AI promises breakthroughs in curing cancer, but current predictive models lack the necessary human biological data to be truly effective. Vivodyne, a biotech startup spun out of the University of Pennsylvania, is addressing this by building robotic labs that grow and test human tissue, generating vital data to improve AI drug discovery.
- Vivodyne’s robotic labs grow 20 types of human tissue for testing
- Their data shows high predictive accuracy matching human trials
- Company raised nearly $80M and launched a large human data center
What happened
Vivodyne, a biotech startup founded by bioengineer Andrei Georgescu, has developed HIVE, a system of modular robotic labs designed to grow and test human tissues autonomously. This approach allows the company to generate biological data directly from living human tissue rather than relying on animal tests or isolated cellular studies. The startup’s tissues, such as liver, airway, and bone marrow, demonstrate high predictive accuracy for drug effects when compared to human clinical trial data.
After raising nearly $80 million from investors including Khosla Ventures, Vivodyne recently opened what it calls the world’s largest human data center near San Francisco. The company claims its system can produce data at twice the throughput of all U.S. animal drug trials combined, working with several major pharmaceutical companies to improve drug candidate screening and reduce costly clinical trial failures.
Why it matters
Vivodyne’s approach directly addresses this gap by providing rich, dynamic human tissue data that can improve predictive models, potentially increasing success rates before clinical trials begin. This breakthrough could accelerate the development of effective cancer drugs and other therapies by enabling more accurate early-stage testing, reducing costs and time wasted on ineffective candidates.
What to watch next
Industry observers will be closely following Vivodyne’s collaboration with pharmaceutical companies and the real-world impact of its human tissue data on drug discovery pipelines. The ability of its AI models, trained on this novel data set, to predict human responses more reliably than current methods will be a key indicator of the company’s disruptive potential.
Additionally, progress from related ventures like Isomorphic Labs, which seeks to build on breakthroughs such as AlphaFold, will offer insight into how AI and biologically relevant data integrate to accelerate drug development. Vivodyne’s next milestones include scaling up data generation and demonstrating that its predictive accuracies translate into higher clinical trial success rates.